These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 29541918)

  • 1. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target.
    Apps JR; Carreno G; Gonzalez-Meljem JM; Haston S; Guiho R; Cooper JE; Manshaei S; Jani N; Hölsken A; Pettorini B; Beynon RJ; Simpson DM; Fraser HC; Hong Y; Hallang S; Stone TJ; Virasami A; Donson AM; Jones D; Aquilina K; Spoudeas H; Joshi AR; Grundy R; Storer LCD; Korbonits M; Hilton DA; Tossell K; Thavaraj S; Ungless MA; Gil J; Buslei R; Hankinson T; Hargrave D; Goding C; Andoniadou CL; Brogan P; Jacques TS; Williams HJ; Martinez-Barbera JP
    Acta Neuropathol; 2018 May; 135(5):757-777. PubMed ID: 29541918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent adamantinomatous craniopharyngiomas show MAPK pathway activation, clonal evolution and rare TP53-loss-mediated malignant progression.
    Apps JR; Gonzalez-Meljem JM; Guiho R; Pickles JC; Prince E; Schwalbe E; Joshi N; Stone TJ; Ogunbiyi O; Chalker J; Bassey A; Otto G; Davies R; Hughes D; Brandner S; Tan E; Lee V; Hayhurst C; Kline C; Castellano S; Hankinson T; Deutschbein T; Jacques TS; Martinez-Barbera JP
    Acta Neuropathol Commun; 2024 Aug; 12(1):127. PubMed ID: 39127699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Analyses Reveal Inflammatory Mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma.
    Donson AM; Apps J; Griesinger AM; Amani V; Witt DA; Anderson RCE; Niazi TN; Grant G; Souweidane M; Johnston JM; Jackson EM; Kleinschmidt-DeMasters BK; Handler MH; Tan AC; Gore L; Virasami A; Gonzalez-Meljem JM; Jacques TS; Martinez-Barbera JP; Foreman NK; Hankinson TC;
    J Neuropathol Exp Neurol; 2017 Sep; 76(9):779-788. PubMed ID: 28859336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma.
    Andoniadou CL; Gaston-Massuet C; Reddy R; Schneider RP; Blasco MA; Le Tissier P; Jacques TS; Pevny LH; Dattani MT; Martinez-Barbera JP
    Acta Neuropathol; 2012 Aug; 124(2):259-71. PubMed ID: 22349813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adamantinomatous craniopharyngioma: moving toward targeted therapies.
    Hengartner AC; Prince E; Vijmasi T; Hankinson TC
    Neurosurg Focus; 2020 Jan; 48(1):E7. PubMed ID: 31896087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular and cellular pathogenesis of adamantinomatous craniopharyngioma.
    Martinez-Barbera JP
    Neuropathol Appl Neurobiol; 2015 Oct; 41(6):721-32. PubMed ID: 25611703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 60 YEARS OF NEUROENDOCRINOLOGY: Biology of human craniopharyngioma: lessons from mouse models.
    Martinez-Barbera JP
    J Endocrinol; 2015 Aug; 226(2):T161-72. PubMed ID: 25926515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivin.
    Stache C; Bils C; Fahlbusch R; Flitsch J; Buchfelder M; Stefanits H; Czech T; Gaipl U; Frey B; Buslei R; Hölsken A
    Neurosurg Focus; 2016 Dec; 41(6):E14. PubMed ID: 27903123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Simvastatin on Inflammatory Response and Biological Behaviour of Adamantinomatous Craniopharyngioma.
    Li W; Zhang Y; Zhuang Y; Chen R; Xiong Z; Li K; Liu F; Xu H; Li D; Peng J
    Neuroendocrinology; 2024; 114(10):934-949. PubMed ID: 38964285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological Behaviour of Craniopharyngiomas.
    Martinez-Barbera JP; Andoniadou CL
    Neuroendocrinology; 2020; 110(9-10):797-804. PubMed ID: 32126562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.
    Coy S; Rashid R; Lin JR; Du Z; Donson AM; Hankinson TC; Foreman NK; Manley PE; Kieran MW; Reardon DA; Sorger PK; Santagata S
    Neuro Oncol; 2018 Jul; 20(8):1101-1112. PubMed ID: 29509940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential Expression of Stem Cell Markers in Human Adamantinomatous Craniopharyngioma and Pituitary Adenoma.
    Chang CV; Araujo RV; Cirqueira CS; Cani CM; Matushita H; Cescato VA; Fragoso MC; Bronstein MD; Zerbini MC; Mendonca BB; Carvalho LR
    Neuroendocrinology; 2017; 104(2):183-193. PubMed ID: 27161333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin‑6 induces an epithelial‑mesenchymal transition phenotype in human adamantinomatous craniopharyngioma cells and promotes tumor cell migration.
    Zhou J; Zhang C; Pan J; Chen L; Qi ST
    Mol Med Rep; 2017 Jun; 15(6):4123-4131. PubMed ID: 28487953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD47 promotes the proliferation and migration of adamantinomatous craniopharyngioma cells by activating the MAPK/ERK pathway, and CD47 blockade facilitates microglia-mediated phagocytosis.
    Zhang H; Wang C; Fan J; Zhu Q; Feng Y; Pan J; Peng J; Shi J; Qi S; Liu Y
    Neuropathol Appl Neurobiol; 2022 Jun; 48(4):e12795. PubMed ID: 35156226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathology and pathogenesis of craniopharyngiomas.
    Larkin SJ; Ansorge O
    Pituitary; 2013 Mar; 16(1):9-17. PubMed ID: 22886701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of enamel proteins and LEF1 in adamantinomatous craniopharyngioma: evidence for its odontogenic epithelial differentiation.
    Sekine S; Takata T; Shibata T; Mori M; Morishita Y; Noguchi M; Uchida T; Kanai Y; Hirohashi S
    Histopathology; 2004 Dec; 45(6):573-9. PubMed ID: 15569047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stem cell senescence drives age-attenuated induction of pituitary tumours in mouse models of paediatric craniopharyngioma.
    Gonzalez-Meljem JM; Haston S; Carreno G; Apps JR; Pozzi S; Stache C; Kaushal G; Virasami A; Panousopoulos L; Mousavy-Gharavy SN; Guerrero A; Rashid M; Jani N; Goding CR; Jacques TS; Adams DJ; Gil J; Andoniadou CL; Martinez-Barbera JP
    Nat Commun; 2017 Nov; 8(1):1819. PubMed ID: 29180744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adamantinomatous craniopharyngioma cyst fluid can trigger inflammatory activation of microglia to damage the hypothalamic neurons by inducing the production of β-amyloid.
    Ainiwan Y; Chen Y; Mao C; Peng J; Chen S; Wei S; Qi S; Pan J
    J Neuroinflammation; 2022 May; 19(1):108. PubMed ID: 35525962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the Canonical Wnt Pathway Activation on the Pathogenesis and Prognosis of Adamantinomatous Craniopharyngiomas.
    Jucá CEB; Colli LM; Martins CS; Campanini ML; Paixão B; Jucá RV; Saggioro FP; de Oliveira RS; Moreira AC; Machado HR; Neder L; Antonini SR; de Castro M
    Horm Metab Res; 2018 Jul; 50(7):575-581. PubMed ID: 29625497
    [No Abstract]   [Full Text] [Related]  

  • 20. Adamantinomatous craniopharyngioma: pathology, molecular genetics and mouse models.
    Martinez-Barbera JP; Buslei R
    J Pediatr Endocrinol Metab; 2015 Jan; 28(1-2):7-17. PubMed ID: 25503464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.